Announcement PDF ABN 16 165 160 841 ASX RELEASE 6 August 2025 POSITIVE ACCENT TRIAL TOPLINE DATA RELEASED HIGHLIGHTS • Progression Free Survival (PFS) of 7.6 months has been determined with current data which represents a 2-month improvement over chemotherapy alone (benchmark MPACT study) • Days on Trial (DOT) of 202 days is a material improvement on chemotherapy alone (117 days) • Objective Response Rate (ORR) currently at 31%, is significantly better compared to chemotherapy alone (23%), with 17 patients still on study • Excellent tolerability profile apparent with adverse events being very similar in type and occurrence to those observed for chemotherapy alone • Disease Control Rate (DCR) of 73% is superior to that observed in the MPACT study (50%) • Further patient updates from the ACCENT trial expected in 2H 2025 and mature data expected in Q1 2026 • Company accelerating towards potential initiation of pivotal phase 2b/3 trial in 2H 2026 Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new interim data from the ongoing ACCENT clinical trial in advanced pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane®. In addition to the 31% ORR previously reported, including a confirmed Complete Response and a pathological Complete Response 1, topline data, available up to 20 July 2025, has now been analysed. Key findings are as follows: 1 2 • The adverse event profile of the narmafotinib combination is very similar to adverse events previously reported for the chemotherapy combination of gemcitabine and Abraxane, in both type of event, rate of occurrence and severity. Narmafotinib treatment results in negligible patient burden in the majority of patients. • Durability of response is excellent with, at this time, 7 patients having stayed on trial for >12 months. The mean Days on Trial for evaluable patients is 202 days, substantially better than the 117 days reported for chemotherapy alone in the benchmark MPACT study 2. At data cutoff 17 patients remained on trial. • The interim PFS analysis indicates a median PFS of 7.6 months, two months better than previously reported for chemotherapy alone. Importantly, this is also superior to the PFS obtained with the more aggressive, but less well tolerated, FOLFIRINOX chemotherapy. ASX Release 11 July 2025 New England Journal of Medicine 2013, 369, 1691 – 703 Level 5, 90 William Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com ACCENT Trial MPACT Trial NAPOLI 3 PRODIGE Trial 7.6 months 5.5 months 5.6 months 6.4 months (Narmafotinib/Gemcitabine/ Abraxane) PFS (Gemcitabine/ Abraxane) (Gemcitabine/ Abraxane) 3 (FOLFIRINOX) 4 Amplia CEO and MD Dr Chris Burns commented: “The data from the ACCENT trial of narmafotinib combined with chemotherapy continues to out-perform chemotherapy alone across a variety of measures. A PFS of 7.6 months at this interim stage of the trial is a significant improvement on existing chemotherapy regimens. We will provide further updates on the data as the trial matures.” This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein overexpressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. About the ACCENT Trial The ACCENT trial is entitled ‘A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients’. The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, determined an optimal dose of narmafotinib (AMP945) by assessing the safety, tolerability, pharmacokinetics and preliminary efficacy when dosed in combination with gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The second stage (Phase 2a) of the trial is designed to assess efficacy in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and safety and tolerability, with secondary endpoints including Progression Free Survival (PFS), Overall Survival (OS) and Duration on Trial (DOT). The trial is being conducted at seven sites in Australia and five sites in South Korea. More information about the ACCENT trial can be found via the ACCENT trial site, the Amplia Therapeutics website and at ClinicalTrials.gov under the identifier NCT05355298. The Company will provide further updates on the trial as data is accrued. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com 3 4 The Lancet 2023, 402(10409), 1272-1281 New England Journal of Medicine 2011, 364, 1817-1825 Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx) and LinkedIn. ACCENT TRIAL TOPLINE DATA August 2025 ampliatx.com | @ampliatx 1 DISCLAIMER This presentation (Presentation) contains summary information about Amplia Therapeutics market, regulatory and other relevant environments that will exist and affect Amplia’s business and Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 operations in the future. The Company does not give any assurance that the assumptions will prove June 2025. By attending an investor presentation or briefing, or accepting, accessing or reviewing to be correct. There may be other factors that could cause actual results or events not to be as this Presentation, you acknowledge and agree to the terms set out below. anticipated, and many events are beyond the reasonable control of the Company. Readers are Summary Information: This Presentation has been prepared for information purposes only and is cautioned not to place undue reliance on forward-looking statements. Forward-looking statements a summary only. It should be read in conjunction with Amplia’s most recent financial report and in this Presentation are only made as at the date of this Presentation and the Company does not other periodic and continuous disclosure information lodged with the Australian Securities undertake any obligation to publicly update or revise any of the forward-looking statements or to Exchange (ASX), which is available at www.asx.com.au. Subject only to any legal obligation to do so, advise of any change in assumptions on which any such statement is based. the Company does not have any obligation to correct or update the content of this Presentation. Industry data and third party information: Industry data and third party information used in this Not financial product advice: This Presentation does not, and does not purport to, contain all Presentation may have been obtained from research, surveys, reports or studies conducted by third information necessary to make an investment decision, is not intended as investment or financial parties, including industry or general publications. Neither Amplia not its representatives have advice (nor tax, accounting or legal advice) and must not be relied upon as such. This Presentation independently verified any such market or industry data. does not take into account the investment objectives, financial situation or needs of any particular Financial Information: This Presentation contains historical financial information based on the investor. Investors are encouraged to seek independent professional advice when deciding if an Company’s results for the 12 month period ending 30 June 2025 and management accounts to 30 investment in the Company is appropriate. The Company is not licensed to provide financial June 2025. All financial information disclosed in this Presentation is presented in Australian dollars product advice in respect of its own securities. This Presentation is not a prospectus, product unless otherwise noted. Any discrepancies between totals and sums of components in tables and disclosure statement or other offering document under Australian law (or any other law). It is not, figures contained in this Presentation are due to rounding. and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any Disclaimer: To the maximum extent permitted by law, Amplia and its officers, directors, employees, jurisdiction. agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any Investment risk and past performance: An investment in Amplia shares is subject to known and liability arising from fault, negligence or negligent misstatement) for any loss arising from this unknown risks, some of which are beyond the control of the Company and its directors. The Presentation or reliance on anything contained in or omitted from it or otherwise arising in Company does not guarantee any particular rate of return or the performance of Amplia. Past connection with this Presentation; (2) disclaim any obligation or undertaking to release any update performance is not, and should not be relied on as being, indicative of future performance. or revision to the information in this Presentation to reflect any change in expectations or Future performance and forward-looking statements: This Presentation includes forward assumptions; and (3) do not make any representation or warranty, express or implied, as to the looking statements, which can generally be identified by the use of words such as “may”, “will”, accuracy, reliability, completeness of the information in this Presentation or that this Presentation “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other contains all material information about Amplia or that a prospective investor or purchaser may similar words. They may include, without limitation, statements regarding plans, strategies and require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of objectives and anticipated business developments. Forward-looking statements inherently involve fulfilment of any forward-looking statement. known and unknown risks, uncertainties and other factors that may cause Amplia’s actual results, performance and achievements to differ materially from statements in this Presentation. Forwardlooking statements are based on the Company’s good faith assumptions as to the financial, 2 EXECUTIVE SUMMARY Developing a pipeline of small molecule inhibitors of FAK Lead drug narmafotinib is best-in-class FAK inhibitor in development Promising efficacy, durability and tolerability in Phase 2a ACCENT clinical trial in pancreatic cancer US trial of narmafotinib in pancreatic cancer to start imminently FAST-track and Orphan Drug Designation granted from US FDA 6 3 METASTATIC PANCREATIC CANCER Limited treatment options; poor patient outcomes 5Y Survival Limited Treatment Options Treatment 3% Gemcitabine + Abraxane ® Median Overall Survival 5.5 months 8.5 months 6.4 months 11.1 months Tolerability (MPACT study) FOLFIRINOX (Prodige study) Highly aggressive with multiple genetic drivers Median Progression Free Survival Most patients receive gemcitabine + Abraxane or FOLFIRINOX or variations of these † >50% pancreatic cancer patients diagnosed with advanced (metastatic, stage 4) disease at the time of diagnosis Other regimens 20% 5-FU treatments 2.2% Gem + Abraxane 46.4% FOLFIRINOX 18.9% Gemcitabine 12.4% MPACT Trial - N Engl J Med. 2013, 369, 1691-703; PRODIGE trial - N Engl J Med. 2011, 364, 1817-1825; † - The Oncologist 2022, 27, 469–475 4 THE AMPLIA ADVANTAGE Three critical features Efficacy Narmafotinib Tolerability Durability 5 ACCENT TRIAL IN PANCREATIC CANCER Phase 1b/2a study in Australia and Korea Intermittent dosing schedule OBJECTIVE narmafotinib To determine safety and efficacy of narmafotinib when added to standard of care in newly diagnosed patients Gemcitabine + Abraxane PRIMARY ENDPOINTS Safety, Tolerability ORR (RECIST 1.1)* ADDITIONAL ENDPOINTS Duration on Trial Progression free survival (PFS) Overall Survival (OS) Disease Control Rate * ORR - Objective Response Rate; RECIST - Response Evaluation Criteria in Solid Tumours, Eur J Canc. 2009, 45, 228-247. 28 Day cycle 6 ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Progression Free Survival (PFS) data All ACCENT patients @ 400 mg (n = 64) Currently determined at 7.6 months substantially better than chemotherapy alone (5.5 months) Improvement over FOLFIRINOX chemotherapy (6.4 months) PFS ACCENT Trial MPACT Trial PRODIGE Trial (Narmafotinib/Gemcitabine/Abraxane) (Gemcitabine/Abraxane) (FOLFIRINOX) 7.6 months 5.5 months 6.4 months PFS data calculation included patients from Phase 1b dosed with narmafotinib (400 mg) and all patients in Phase 2a. Interim data based on data cut-off 20 Jul 2025. 7 ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Includes: 1 confirmed Complete Response (CR) 1 pathological Complete Response (pCR) Indicating narmafotinib + chemotherapy is superior to chemotherapy alone 7 patients on study > 1 year Mean DoT = 201 days Individual Patients 17 confirmed responses observed to date At data cut-off (20 Jul 2025): 17 patients remain on study Data for 6 patients at 6 months yet to be collected Interim data based on data cut-off 20 Jul 2025. Only evaluable patients shown. Responses are investigator read. DoT - Duration on Trial, PR - Partial Response; SD - Stable Disease, PD - Progressive Disease. 8 ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Excellent response rate observed 1 confirmed Complete Response 16 confirmed Partial Responses Incl. 1 patient determined to be a pathological Complete Response Objective response rate (ORR) of 31% Disease control rate (DCR) of 73% * Individual Patients Interim data based on data cut-off Jul 20, 2025. Responses are investigator read * Pathological Complete Response 9 ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Excellent response rate observed 1 confirmed Complete Response 16 confirmed Partial Responses Incl. 1 patient determined to be a pathological Complete Response Objective response rate (ORR) of 31% Disease control rate (DCR) of 73% * Individual Patients Interim data based on data cut-off Jul 20, 2025. Responses are investigator read. NE - Non-evaluable ACCENT Trial MPACT Trial (Narmafotinib/Gemcitabine/Abraxane) (Gemcitabine/Abraxane) CR 2% 0.2% PR 29% 23% SD 42% 27% PD 16% 20% NE 11% 30% ORR 31% 23% DCR 73% 50% DOT 202 days 117 days * Pathological Complete Response 10 ACCENT TRIAL TOPLINE DATA Promising evidence of efficacy, durability and tolerability Excellent tolerability observed to date Narmafotinib treatment results in negligible extra patient burden Adverse Events (Grade 3 or above) Adverse Event (AE) Grade ≥ 3 Narmafotinib +Gem/Abr (ACCENT; N=55) Gem/Abr (MPACT; N=421) Gem/Abr (NAPOLI 3; N=379) FOLFIRINOX (PRODIGE; N=171) NALIRIFOX (NAPOLI 3; N=370) Neutropenia 38.2% 38% 39% 46% 24% Anemia 9.1% 13% 18% 8% 11% Diarrhea 5.5% 6% 5% 13% 20% Peripheral neuropathy 3.6% 17% 6% 9% 3% Vomiting 3.6% NR 2% 15% 7% Febrile Neutropenia 5.5% 3% NR 5% NR Thrombocytopenia NR 13% NR 9% NR Fatigue NR 17% 5% 24% 6% Hypokalemia NR NR 4% NR 15% Nausea 3.6% NR 3% NR 12% ACCENT and MPACT trials have very similar inclusion criteria and trial designs however no head-to-head clinical trial has been conducted. Differences exist between ACCENT and other trials in design, inclusion criteria 11 and patient demographics. NR - Not Reached. NAPOLI 3 Trial - The Lancet 2023, 402(10409),1272-1281 ACCENT TRIAL SUMMARY On track to achieve trial goals Superior Efficacy For full 55 patient cohort 1 CR 16 PR (incl. 1 pCR) Improved PFS over Gemcitabine + Abraxane, and FOLFIRINOX Improved Durability 7 patients on trial for >12 months Deep and sustained response for a subset of patients Biomarker discovery to be initiated Demonstrated Tolerability Excellent tolerability profile Minimal additional burden on the patients above standard of care No evidence or likelihood of drug-drug interactions 12 FUTURE OPPORTUNITIES FAK inhibition will enhance multiple therapeutic strategies Narmafotinib (FAK inhibition) CHEMOTHERAPY IMMUNOTHERAPIES Clinical and preclinical data incl. ACCENT study Preclinical data RADIOTHERAPY KRAS INHIBITORS Published data Preclinical data, incl. collaboration ANTIBODY DRUG CONJUGATES Published data 13 AMPLICITY TRIAL in mPDAC Phase 1b/2a study in the US and Australia OBJECTIVE To determine safety and efficacy of narmafotinib when added to FOLFIRINOX in newly diagnosed patients To identify recommended phase 2 dose (RP2D) Moving from intermittent to daily dosing narmafotinib FOLFIRINOX PRIMARY ENDPOINTS Safety, Tolerability RP2D ADDITIONAL ENDPOINTS ORR (RECIST v1.1) Duration of Response Progression free survival (PFS) Overall Survival (OS) Disease Control Rate 14 Day cycle 14 NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR FAK enzyme overactive in pancreatic cancer Benefits of FAK Inhibition FAK levels are elevated in pancreatic cancer Correlate with worse patient outcome Anti-proliferative Reduces cells’ ability to proliferate and migrate Synergy with chemotherapies Enhances activity of drugs and other therapies FAK inhibition blocks processes that support: Tumour growth Metastasis Treatment resistance Demonstrated efficacy in preclinical models of human pancreatic cancer FAK - Focal Adhesion Kinase Tumour (blue - cancer cells; green- fibroblasts; purple, grey and yellow - suppressive immune cells) Anti-fibrotic Reduces scar-tissue in TME, improving permeability to drugs Immunomodulatory Improves immune cell reactivity to tumour cells 15 NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR Best-in-class profile Convenient to take Once a day oral dosing by capsule Storage at room temperature Safe to combine with other medicines No evidence of drug-drug interactions Evidence of FAK target engagement preclinically and in the clinic 16 UPCOMING MILESTONES Q3 2025 ACCENT top-line data Q4 2025 Q1 2026 Q2 2026 ACCENT further patient ACCENT mature data ACCENT trial completion updates (including OS) possible ACCENT request FDA type C meeting - Phase 2b/3 AMPLICITY first trial data AMPLICITY complete AMPLICITY further dose escalation patient updates FDA meeting and minutes ACCENT trial pathway dosed (part A) ACCENT further patient begins IIT data updates (kRAS and Ovarian) Initiate kRAS combination Initiate IIT in ovarian IIT cancer IIT funding outcome(s) updates ACCENT full data release AMPLICITY 2-dose comparison trial pivotal trial design AMPLICITY first patient 2H 2026 ACCENT Phase 2b/3 trial planning finalised EU regulatory response Drug product scale-up Possible EU regulatory filings ACCENT Phase 2b/3 trial protocol finalised 17 THANK YOU Chris Burns PhD GAICD FAHMS CEO and MD Rhiannon Jones PhD GAICD COO chris@ampliatx.com​ rhiannon@ampliatx.com​ Amplia Therapeutics Limited​ ASX: ATX​ info@ampliatx.com ampliatx.com 18